Peer-reviewed veterinary case report
Imepitoin controls seizures in dogs with fewer side effects than
By Tipold, A et al.·Published in Journal of veterinary pharmacology and therapeutics·2015·Department of Small Animal Medicine and Surgery, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical efficacy and safety of imepitoin in comparison with phenobarbital for the control of idiopathic epilepsy in dogs.
- Species:
- dog
Plain-English summary
A group of dogs with idiopathic epilepsy (a type of seizure disorder) were treated with either imepitoin or phenobarbital to see which medication worked better for controlling their seizures. The study found that imepitoin was just as effective as phenobarbital, but with fewer side effects like sedation and increased appetite. Dogs taking phenobarbital also showed higher levels of liver enzymes, indicating potential liver issues, while those on imepitoin did not. Overall, imepitoin was found to be a safe and effective option for managing seizures in dogs.
People also search for: dog seizure treatment · imepitoin for dogs · phenobarbital side effects in dogs
Abstract
The anticonvulsant activity and safety of imepitoin, a novel antiepileptic drug licensed in the European Union, were evaluated in a multicentre field efficacy study as well as in a safety study under laboratory conditions. Efficacy of imepitoin was compared with phenobarbital in 226 client-owned dogs in a blinded parallel group design. The administration of imepitoin twice daily in incremental doses of 10, 20 or 30 mg/kg demonstrated comparable efficacy to phenobarbital in controlling seizures in dogs. The frequency of adverse events including somnolence/sedation, polydipsia and increased appetite was significantly higher in the phenobarbital group. In phenobarbital-treated dogs, significantly increased levels of alkaline phosphatase, gamma-glutamyl-transferase and other liver enzymes occurred, while no such effect was observed in the imepitoin group. In a safety study under laboratory conditions, healthy beagle dogs were administered 0, 30, 90 or 150 mg/kg imepitoin twice daily for 26 weeks. A complete safety evaluation including histopathology was included in the study. A no-observed-adverse-event level of 90 mg/kg twice daily was determined. These results indicate that imepitoin is a potent and safe antiepileptic drug for dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25079881/